December 2017: Promotion of Monofer Solution for injection & infusion (Iron Isomaltoside) by Pharmacosmos Representative
Published 22 February 2018
© Crown copyright 2018
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-december-2017/december-2017-promotion-of-monofer-solution-for-injection-infusion-iron-isomaltoside-by-pharmacosmos-representative
MHRA received a complaint from a healthcare professional via the Prescription Medicines Code of Practice Authority (PMCPA) concerning the promotion of Monofer by a Pharmacosmos representative. The healthcare professional alleged that the material presented included disparaging and unsubstantiated comparisons with a rival product (Ferinject) with regard to the incidence of hypophosphataemia compared to Monofer.
MHRA did not uphold the complaint. The material used by the Pharmacosmos representative was considered to provide accurate information on what is known about the effects of Monofer on phosphate levels.